Analysis of C-reactive protein levels and febrile tendency after joint surgery in rheumatoid arthritis patients treated with a perioperative 4-week interruption of tocilizumab

Modern Rheumatology

Volumn 21, Issue 1, 2011, Pages 109-111

  Hiroshima, Ryo ^a   Kawakami, Kosei ^a   Iwamoto, Takuji ^a   Tokita, Asami ^a   Yano, Koichiro ^a   Sakuma, Yu ^a   Ikari, Katsunori ^a   Momohara, Shigeki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Anti IL 6 receptor blocker; C reactive protein; Orthopedic joint surgery; Rheumatoid arthritis; Tocilizumab

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PREDNISOLONE; TOCILIZUMAB;

ADULT; AGED; ARTHROPLASTY; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FEVER; FOOT SURGERY; HUMAN; INFECTION RISK; JOINT SURGERY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SURGICAL INFECTION; SURGICAL PATIENT; SURGICAL RISK; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT WITHDRAWAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROPLASTY, REPLACEMENT; C-REACTIVE PROTEIN; FEMALE; FEVER; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 79951944411     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-010-0343-1     Document Type: Article

References (14)

1. N Nishimoto N Miyasaka K Yamamoto S Kawai T Takeuchi J Azuma 2009 Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study Ann Rheum Dis 68 10 1580 1584 1:CAS:528:DC%2BD1MXhtlKqtbnE 10.1136/ard.2008.092866 19019888
2. P Emery E Keystone HP Tony A Cantagrel R van Vollenhoven A Sanchez, et al. 2008 IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial Ann Rheum Dis 67 11 1516 1523 1:CAS:528:DC%2BD1cXhtl2gsbbI 10.1136/ard.2008.092932 18625622
3. G Jones A Sebba J Gu MB Lowenstein A Calvo JJ Gomez-Reino, et al. 2010 Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study Ann Rheum Dis 69 1 88 96 1:CAS:528:DC%2BC3cXhtFOls78%3D 10.1136/ard.2008.105197 19297346
4. JS Smolen A Beaulieu A Rubbert-Roth C Ramos-Remus J Rovensky E Alecock, et al. 2008 Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial Lancet 371 9617 987 997 1:CAS:528:DC%2BD1cXjs1Sltbc%3D 10.1016/S0140-6736(08)60453-5 18358926 (Pubitemid 351392039)
5. MC Genovese JD McKay EL Nasonov EF Mysler NA da Silva E Alecock, et al. 2008 Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study Arthritis Rheum 58 10 2968 2980 1:CAS:528:DC%2BD1cXht12rur%2FJ 10.1002/art.23940 18821691
6. AA den Broeder MC Creemers J Fransen E de Jong DJ de Rooij A Wymenga, et al. 2007 Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study J Rheumatol 34 4 689 695 (Pubitemid 46641372)
7. Y Hirano T Kojima Y Kanayama T Shioura M Hayashi D Kida, et al. 2010 Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis Clin Rheumatol 29 5 495 500 10.1007/s10067-009-1346-1 20069328
8. JT Giles SJ Bartlett AC Gelber S Nanda K Fontaine V Ruffing, et al. 2006 Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis Arthritis Rheum 55 2 333 337 10.1002/art.21841 16583385
9. A Ruyssen-Witrand L Gossec C Salliot M Luc M Duclos S Guignard, et al. 2007 Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers Clin Exp Rheumatol 25 3 430 436 1:STN:280:DC%2BD2svhtlagtw%3D%3D 17631740 (Pubitemid 47091020)
10. K Kawakami K Ikari K Kawamura S Tsukahara T Iwamoto K Yano, et al. 2010 Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatology (Oxford) 49 2 341 347 1:CAS:528:DC%2BC3cXntleqsw%3D%3D 10.1093/rheumatology/ kep376
11. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999;20(4):250-78 (quiz 279-80).
12. M Hirao J Hashimoto H Tsuboi A Nampei H Nakahara N Yoshio, et al. 2009 Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab Ann Rheum Dis 68 5 654 657 1:CAS:528:DC%2BD1MXls1ChurY%3D 10.1136/ard.2008.090068 18519424
13. J Ledingham C Deighton 2005 Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001) Rheumatology (Oxford) 44 2 157 163 1:STN:280:DC%2BD2M%2FlsVSksA%3D%3D 10.1093/rheumatology/ keh464 (Pubitemid 40277395)
14. R Koike T Takeuchi K Eguchi N Miyasaka 2007 Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis Mod Rheumatol 17 6 451 458 1:CAS:528:DC%2BD1cXisFCjtbo%3D 10.1007/s10165-007-0626-3 18084695